IMNN Imunon, Inc.
$1.47▲ +1.38%
Healthcare
Other
After hours
$1.50▲ +2.04%
Sep 11, 7:55 PM ET
Volume 129.2K
Avg Volume (10D) 140.3K
Key Metrics & Fundamentals
Market Cap
$8.25M
P/E Ratio
–
Div Yield
–%
52W Range
1.39 - 5.85
% vs 50 MA
-12.05%
% vs 200 MA
-45.44%
RSI-14
35.9
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.56
Free Cash Flow
-$3.99M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.20M
COGS
–
Operating Exp
$4.31M
Operating Income
-$4.31M
EBIT
-$4.31M
Pretax Income
-$4.25M
Net Income
-$4.25M
EPS (Diluted)
-0.84
Price & Volume History
Loading chart…
Recent News
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
GlobeNewswire · Sep 10, 2026 1:30 PM
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
GlobeNewswire · Sep 9, 2026 12:30 PM
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
GlobeNewswire · Aug 26, 2026 12:30 PM
IMNN: Strong Enrollment Momentum Continuing for Phase 3 OVATION 3 Trial
Zacks Small Cap Research · Aug 19, 2026 12:10 PM
Imunon (IMNN) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 2:12 AM
Imunon, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 11, 2026 4:52 PM
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 11, 2026 12:00 PM
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
GlobeNewswire · Aug 4, 2026 12:00 PM
Imunon Reports Enrollment Above Expectations in Phase 3 Trial of IMNN-001 to Treat Ovarian Cancer
MT Newswires · Jul 30, 2026 2:11 PM
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
GlobeNewswire · Jul 30, 2026 1:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See IMNN's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.